Strides

July 31, 2026

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051, Maharashtra.

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001, Maharashtra.

Symbol: STAR

Scrip Code: 532531

Dear Madam/ Sir,

Sub: Press Release

Please find enclosed herewith Press Release issued by the Company titled:

"Strides Delivers Steady Performance with Q1FY27; Revenue at ₹12,654m, Grew 13% YoY; Ex-US Markets Grew 17% YoY"

The Board Meeting for considering the unaudited financial results for the quarter ended June 30, 2026 commenced at 10:30 hrs IST and concluded at 12:30 hrs IST.

The above information shall be made available on the website of the Company at www.strides.com.

This is for your information and records.

Thanks & Regards,
For **Strides Pharma Science Limited,**

MANJULA RAMAMURTHY
Digitally signed by MANJULA RAMAMURTHY
Date: 2026.07.31 12:31:57 +05'30'

Manjula Ramamurthy
Company Secretary & Compliance Officer
ICSI Membership No.: A30515

Encl. As above

Strides

Strides Delivers Steady Performance with Q1FY27 Revenue at ₹12,654m, Grew 13% YoY; Ex-US Markets Grew 17% YoY

EBITDA Grew 5.4% YoY to ₹2,298m, Despite a ~₹131m Impact on Freight and Operating Costs from Geopolitical Disruptions

Q1FY27 Performance Highlights

- **Revenue up 13% YoY to ₹12,654m,** led by strong 17% YoY growth in the Ex-US Markets
- **Ex-US Markets revenue at ₹5,875m ($63m),** up 17% YoY, driven by strong performance across markets
- **US business remains steady at ₹6,282m ($68m),** up 4% YoY
- **EBITDA up 5.4% YoY to ₹2,298m,** absorbing a ~₹131m impact on operating costs from the ongoing geopolitical situation; EBITDA margin at 18.2%
- **Operational PAT up 8% YoY to ₹1,231m;** Operational EPS at ₹13.4
- **Reported PAT up 56.7% YoY to ₹1,655m;** Reported EPS at ₹17.0
- **₹1,000m of value unlocked** through the divestment of the majority stake in Pivot Path, Strides' captive GCC, while retaining meaningful participation in its future growth

Bangalore, India, 31 July 2026 - Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q1FY27) ended 30 June, 2026.

Financial Highlights (In ₹m)

Particulars (₹m)	Q1FY27	Q1FY26	YoY	Q4FY26	QoQ
Revenue	12,654	11,197	13.0%	13,235	-4.4%
Gross Margin	7,702	6,755	14.0%	7,872	-2.2%
Gross Margin %	60.9%	60.3%	60 bps	59.5%	140 bps
EBITDA	2,298	2,181	5.4%	2,397	-4.1%
EBITDA %	18.2%	19.5%	-130 bps	18.1%	10 bps
Operational PAT	1,231	1,140	8.0%	1,357	-9.3%
Operational EPS (₹)	13.4	12.4	8.0%	14.7	-9.2%
Reported PAT	1,655	1,056	56.7%	1,293	28.0%
Reported EPS (₹)	17.0	10.8	57.6%	13.8	23.6%

Reported PAT includes gain on sale of majority stake in Pivot Path, Strides captive GCC; Operational PAT = Reported PAT excluding exceptional items

Badree Komandur, MD & Group CEO, commented on the performance and said, "Strides delivered a steady start to FY27 with revenue growth of 13% YoY. Our investments in Ex-US Markets over the past few years are now yielding strong results, delivering 17% YoY growth and reinforcing the strength of our diversified business strategy. Our focus on execution and operating discipline enabled us to grow absolute gross margins by 14% YoY. EBITDA grew ~5% YoY to ₹2,298m, despite ~₹131m impact from elevated operating and freight cost arising from the ongoing geopolitical situation. We remain focused on mitigating these pressures through continuous cost optimization initiatives. We reduced net debt by ₹119m, with Net Debt-to-EBITDA at 1.52x, despite significant working capital investments required to navigate the current business environment and growth. During the quarter, we unlocked ₹1,000m of value through the divestment of our majority stake in Pivot Path, our captive GCC, while retaining meaningful participation in its future growth. We also improved our EcoVadis sustainability score to 68/100, a 19-point increase over last year. While the external environment remains dynamic, we remain focused on delivering sustainable and profitable growth."

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at www.strides.com.

For further information, please contact:

Investor Relations	Corporate Communication
Vikesh Kumar: Group CFO investor-relations@strides.com Saurabh Ambaselkar: +91 99609 31220 saurabh.ambaselkar@strides.com **Strides Pharma Science Limited** Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076	Pallavi Panchmatia: +91 80 6784 0193 Pallavi.panchmatia@strides.com Abhilash Mukherjee: +91 89044 28907 Abhilash.Mukherjee@strides.com Adrita Chatterjee: +91 92842 40813 adrita.chatterjee@adfactorspr.com